Male diabetes patients who underwent androgen deprivation therapy for prostate cancer showed higher A1C at two years compared with those who did not receive ADT, a study found. "Men with diabetes who start ADT should be counseled about the potential need for intensification of diabetes therapy and should have their [A1C] levels monitored during therapy, especially if they continue on long-term ADT," researchers wrote in the journal European Urology.

Related Summaries